Wang Qin, Shaik Firdoz, Lu Xiuxin, Zhang Wenhao, Wu Yafei, Qian Haisheng, Zhang Weiqing
Department of Research, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, China.
Schulich Faculty of Chemistry, Technion Israel Institute of Technology, Haifa 320000, Israel.
Acta Biomater. 2023 Jan 1;155:575-587. doi: 10.1016/j.actbio.2022.10.048. Epub 2022 Oct 29.
The apoptosis-ferroptosis hybrid therapy opens up a new avenue for tumor eradication. Constructing efficient self-cascade platform is highly desired to enhance its therapeutic effect. Herein, we report on the synthesis of novel nanozyme consist of amorphous NiB alloy completely coated with an ultrathin layer of IrOx shell (A-NiB@C-IrO). These core-shell nanoparticles exhibited peroxidase (POD)-, catalase (CAT)- and glutathione oxidase (GSH-OXD)-like properties for inducing self-cascade catalysis. Specifically, the amorphous IrO shell with abundant active sites can effectively convert intratumor hydrogen peroxide (HO) to cytotoxic reactive oxygen species (ROS) and oxygen (O). In presence of O2, amorphous NiB core and ultrathin IrOx shell collectively catalyze the oxidation of GSH to generate HO, which is subsequently converted to ROS and O by IrO component. Thus, these enzymatic activities endow A-NiB@C-IrO nanozymes with the ability of unceasing generation of ROS and O and depletion of GSH. In vitro and in vivo studies demonstrate a high therapeutic efficiency of A-NiB@C-IrO nanozymes via apoptosis-ferroptosis combination therapy. STATEMENT OF SIGNIFICANCE: Apoptosis-ferroptosis hybrid therapy opens up new avenues for eradicating tumor cells. However, its actual therapeutic effect is still unsatisfied. Current efforts on this hybrid therapy focus on developing efficient self-cascade nanozymes to improve the efficiency of both ROS generation and GSH depletion. In this study, we constructed amorphous NiB alloy with a completed thin layer of IrO shell (denoted as A-NiB@C-IrO) for apoptosis-ferroptosis combination therapy. As expected, A-NiB@C-IrO can trigger efficient cascade catalytic reactions to continuously generate ROS and consume GSH, finally inducing augmented apoptosis-ferroptosis combination therapy.
凋亡-铁死亡联合疗法为根除肿瘤开辟了一条新途径。构建高效的自级联平台对于增强其治疗效果具有迫切需求。在此,我们报道了一种新型纳米酶的合成,该纳米酶由完全包覆有超薄 IrOx 壳层的非晶态 NiB 合金组成(A-NiB@C-IrO)。这些核壳纳米颗粒表现出类似过氧化物酶(POD)、过氧化氢酶(CAT)和谷胱甘肽氧化酶(GSH-OXD)的性质,可诱导自级联催化。具体而言,具有丰富活性位点的非晶态 IrO 壳层能够有效地将肿瘤内的过氧化氢(H₂O₂)转化为具有细胞毒性的活性氧(ROS)和氧气(O₂)。在 O₂存在的情况下,非晶态 NiB 核和超薄 IrOx 壳层共同催化谷胱甘肽(GSH)的氧化以生成 H₂O₂,随后 H₂O₂被 IrO 组分转化为 ROS 和 O₂。因此,这些酶活性赋予 A-NiB@C-IrO 纳米酶不断产生活性氧和氧气以及消耗谷胱甘肽的能力。体外和体内研究表明,A-NiB@C-IrO 纳米酶通过凋亡-铁死亡联合疗法具有很高的治疗效率。重要性声明:凋亡-铁死亡联合疗法为根除肿瘤细胞开辟了新途径。然而,其实际治疗效果仍不尽人意。目前针对这种联合疗法的努力集中在开发高效的自级联纳米酶,以提高活性氧生成和谷胱甘肽消耗的效率。在本研究中,我们构建了具有完整 IrO 壳层的非晶态 NiB 合金(记为 A-NiB@C-IrO)用于凋亡-铁死亡联合疗法。正如预期的那样,A-NiB@C-IrO 能够引发高效的级联催化反应,持续产生活性氧并消耗谷胱甘肽,最终诱导增强的凋亡-铁死亡联合疗法。
Acta Biomater. 2023-1-1
J Colloid Interface Sci. 2024-1
J Nanobiotechnology. 2025-7-28
Int J Nanomedicine. 2025-5-1
Int J Nanomedicine. 2024-12-17
Front Pharmacol. 2024-6-19
Front Pharmacol. 2024-5-6
iScience. 2024-3-11